Pcn84 - Total Cost of Care and Budget Impact for Patients With CLL Treated With Venetoclax

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.166
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Venetoclax: Another Oral Therapy Option for Patients With CLL

Pharmacy Today
2016English

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax Treated CLL in Routine Clinical Practice

Clinical Cancer Research
Cancer ResearchOncology
2019English

Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS and Minimal Residual Disease Negativity in Patients With Previously Untreated CLL and Comorbidities

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Bendamustine (B), Followed by Obinutuzumab (G) and Venetoclax (A) in Patients With Chronic Lymphocytic Leukemia (Cll): Cll2-Bag Trial of the German CLL Study Group (Gcllsg)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Pmd40 - The Budget Impact and Cost-Consequence of Treating Leg Ulcers With Urgostart

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Venetoclax–Obinutuzumab Elicits High Response Rates in CLL

Cancer Discovery
Oncology
2019English

Biclonal IGHV -4-34 Variant Hairy Cell Leukemia and CLL - Successful Treatment With Ibrutinib and Venetoclax

American Journal of Hematology
Hematology
2018English

Pmd41 - The Budget Impact and Cost-Consequence of Treating Diabetic Foot Ulcers With Urgostart

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Extended Follow-Up and Impact of High-Risk Prognostic Factors From the Phase 3 RESONATE Study in Patients With Previously Treated CLL/SLL

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy